Basic concepts in glioma immunology.
Glioblasotmas are the most common primary central nervous system tumor and typically have a dismal prognosis. Immunotherapy has been a promising experimental treatment. Understanding brain tumor immunobiology is critical to designing glioblasotma immunotherapies. In this chapter, we review aspects of basic immunology and neuro-immunology. The antigenic underpinnings of brain tumor immunotherapy including glioma-associated and glioma-specific antigens are discussed. Finally, the molecular and cellular facets of glioma-mediated immunosuppression are outlined. The role of multiple cell types (glioma cells, glioma-infiltrating monocytes, regulatory T cells and myeloid derived suppressor cells) in mediating local and systemic immunosuppression in glioma patients is evaluated.
Department of Neurologic Surgery, Mayo Clinic, Rochester, MN, USA. parney.ian@mayo.edu
Ian F
IF
Parney
D056704:Adaptive Immunity / Q000276:immunology*; D001932:Brain Neoplasms / Q000276:immunology* / Q000628:therapy; D003713:Dendritic Cells / Q000276:immunology / Q000378:metabolism; D005910:Glioma / Q000276:immunology* / Q000628:therapy; D006801:Humans; D007113:Immunity, Innate / Q000276:immunology*; D007167:Immunotherapy / Q000379:methods; D018448:Models, Immunological; D013601:T-Lymphocytes / Q000276:immunology / Q000378:metabolism; D050378:T-Lymphocytes, Regulatory / Q000276:immunology / Q000378:metabolism